Abstract
Purpose: Optimal sequencing of high-dose rate (HDR) brachytherapy (BT) boost and whole pelvis intensity-modulated radiotherapy (IMRT) for definitive treatment of prostate cancer (PCa) is not defined. The prospective Timing of HDR brachytherapy with EBRT in Prostate Cancer (THEPCA) trial is ongoing to address this question. To our knowledge, we present the first report comparing early toxicity and disease outcomes for PCa patients treated with HDR-BT upfront vs. IMRT upfront combined with androgen deprivation therapy (ADT).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
